Kratom, a tropical plant native to Southeast Asia, has become the subject of rising political debate in the United States. The substance, which is currently sold over the counter, is known for producing effects similar to opioids, a characteristic that has prompted concerns among public health officials and legislators. As a result, several states have moved to implement their own bans on the herb and its synthetic derivatives.

The legislative pressure is not limited to the state level. There is a growing push for a federal response to address the availability and safety of the product. Notably, Senator Chuck Grassley (R-Iowa) has formally requested that the executive branch take action to address the risks associated with kratom. This call for federal oversight follows reports that specific compounds derived from the plant have been identified in various contexts, raising alarms about its potential for misuse or adverse health outcomes.

While some advocates argue that kratom can be used for pain management or as a supplement, critics and lawmakers are increasingly focused on its pharmacological profile. The debate centers on whether the substance requires stricter federal control, such as scheduling under the Controlled Substances Act, or if state-level regulations are sufficient to manage public safety concerns. As of now, the federal government has not issued a comprehensive national policy, leaving the regulatory landscape fragmented across different jurisdictions.